|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�ۼ����� |
|
������ԭø�� |
|
�,Ѱ�� |
|
ͺ�� |
|
��ë֢ |
| ��������������� | |
|
����ƽ |
|
��¡�� |
| PubMed | |
|
Article by |
|
Article by |
5��-��ԭø���ۼ��ش�л�е����ü������Ƽ���Ƥ���Ƶ�Ӧ��
����ƽ, ��¡��
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
5��-��ԭø��Ƥ���ۼ��ش�л�Ĺؼ�ø�����������ֶ���Ƥ�������ۼ��ش�л�쳣�йء�һЩ����ҩ���5��-��ԭø���Ƽ�����������ǰ���ټ������ۼ���Դ���ѷ�,Ϊ���������ۼ��������Ƥ�����ṩ�˿��ܡ�������Ƥ�����ۼ��ش�л���������ú�5��-��ԭø���Ƽ���Ƥ�����е�Ӧ�á�
[2] Thiboutot D, Jabara S, McAllister JM, et al. Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol, 2003, 120:905-914.
[3] Thiboutot D, Gilliland K, Light J, et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol,1999, 135:1041-1045.
[4] De Villez RL, Dunn J. Female androgenic alopecia. The 3 alpha,17beta-androstanediol glucuronide/sex hormone binding globulin ratio as a possible marker for female pattern baldness. Arch Dermatol, 1986,122:10ll-1015.
[5] Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and ��, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dennatol, 1997, 109:296-300.
[6] Bayne EK, Flanagan J, Einstein M, et al. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. Br J Dermatol, 1999, 141:481-491.
[7] Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol, 1998,110:849-853.
[8] Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol, 1998, 39:578-589.
[9] Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol, 1999, 41:550-554.
[10] Price VH, Menefee E, Sanchez M, et al. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol, 2002, 46:517-523.
[11] Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol, 2000, 43:768-776.
[12] Wong IL, Morris RS, Chang L, et al. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab, 1995, 80:233-238.
[13] Qian LH, Wang XL, Tu ZH. Atrophy and apoptosis in ventral prostate of rats induced by 5alpha-reductase inhibitor, epristeride. Acta Pharmacol Sin, 2001, 22:399-404.
[14] Graul A,Silvestre J, Castaner J, et al. Dutasteride, steroid 5��-reductase inhibitor, treatment of BPH. Drugs Fut, 1999, 24:246-253.
[15] Fujita T, Matsumoto Y, Kimura T, et al. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol, 2002, 54:283-294.
[16] Hirosumi J, Nakayama O, Chida N, et al. FK.143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (2) In vivo effects on rat and dog prostates. J Steroid Biochem Mol Biol, 1995, 52:365-373.
[17] Sawada K, Okada S, Kuroda A, et al. 4-(Benzoylindolizinyl)butyric acids; novel nonsteroidal inhibitors of steroid 5alpha-reductase. ��.Chem Pharm Bull (Tokyo), 2001,49:799-813.
[18] Niiyama S, Kojima K, Hamada T, et al. The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol, 2000, 10:593-595.
[19] Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol, 2002,19:413-425.